• Hear about policies affecting rare diseases in this evolutionary time: the opportunities, challenges and possible solutions
• Discuss the legislation that, by the time of the meeting, Congress is likely to have enacted, including special provisions applicable to orphan products
• Learn some of the administrative initiatives that FDA is considering that will affect product development and government reviews
• Learn strategies on how you can become a more effective advocate

Featured Speakers Include

Keynote:

• Stephen P. Spielberg, MD, PhD: Deputy Commissioner, Medical Products and Tobacco, Office of the Commissioner, FDA

Plenary:

• Cole Werble, MA: Founding Member, Prevision Policy, LLC
• David P. Meeker, MD: President and Chief Executive Officer, Genzyme
• Charles A. Mohan, Jr.: CEO/Executive Director, The United Mitochondrial Disease Foundation